AstraZeneca shares down 3% after rating cut, UK investment pause
Published by Global Banking and Finance Review
Posted on September 15, 2025
Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Published by Global Banking and Finance Review
Posted on September 15, 2025
By Maggie Fick and Danilo Masoni
LONDON (Reuters) -AstraZeneca shares fell as much as 3.4% on Monday, their steepest drop since May, after Handelsbanken cut its rating on the drugmaker and Reuters reported the company had paused a major investment in its home market.
The Anglo-Swedish pharmaceutical group's stock underperformed the broader European healthcare index, which was down less than 1% at 11 GMT. Handelsbanken lowered its recommendation on AstraZeneca to "hold" from "buy", citing what it sees as an overly optimistic target of $80 billion in total revenue by 2030.
Britain's biggest listed company became the latest drugmaker to pull back on its business in the country after it paused a planned 200 million pound ($272.12 million) investment in its Cambridge research centre, a spokesperson told Reuters late on Friday. The move comes as a blow to Prime Minister Keir Starmer's government ahead of U.S. President Donald Trump's state visit to Britain this week.
Shares were down 2.7% at 1100 GMT.
AstraZeneca, which has a robust drug pipeline of blockbuster cancer medicines, did not immediately respond to a request for comment.
($1 = 0.7350 pounds)
(Reporting by Maggie Fick and Danilo Masoni, Editing by Louise Heavens)